Indivior PLC Ordinary Shares (INDV) Stock: Buy, Sell, or Hold?
INDV - Indivior PLC Ordinary Shares
$35.33
0.54 (1.55%)
▲
5d:
+5.09%
30d:
-1.62%
90d:
-12.82%
BUY
HIGH Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Oct 29, 2026
5d
Get Alerted When INDV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: INDV appears deeply undervalued. Market expects -9.0% annual earnings decline despite 600% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: INDV appears deeply undervalued. Market expects -9.0% annual earnings decline despite 600% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$66.91
Based on 7.4% avg growth
INTRINSIC VALUE TODAY
$41.54
15.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: INDV is currently trading at $35.33, which is considered slightly low relative to its 30-day fair value range of $34.30 to $36.26. From a valuation perspective, the stock is trading at a discount (Forward PE: 7.2) compared to its historical average (9.6). Remarkably, the market is currently pricing in an annual earnings decline of 9.0% over the next few years. This pessimistic expectation contrasts with the company's recent 600% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, INDV is in a strong uptrend. The price is approaching resistance at $36.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: INDV scores 74/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $49.00 (+38.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, INDV is in a strong uptrend. The price is approaching resistance at $36.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: INDV scores 74/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $49.00 (+38.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$34.30 -
$36.26
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (74/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 38.7% below Wall St target ($49.00)
- BULLISH: Bottoming setup score 74/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$34.30 -
$36.26
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$32.31
Resistance Level
$36.32
Current Trend
Strong Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.23
Wall Street Target
$49.00
(+38.7%)
Revenue Growth (YoY)
13.6%
Earnings Growth (YoY)
600.0%
Profit Margin
26.8%
Valuation Discount vs History
-9.0% cheaper
PE vs Historical
7.2 vs 9.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-9.0%
(market-implied from PE analysis)
1-Year Target
$32.15
(-9%)
2-Year Target
$29.26
(-17%)
3-Year Target
$26.62
(-25%)
3-Yr Target (if PE normalizes)
(PE: 7→10)
$35.33
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 10.8%)
$131.80
(+273%)
Base:
(SPY PE: 7.2, Growth: 10.8%)
$48.01
(+36%)
Bear:
(PE: 6.1, Growth: 10.8%)
$40.81
(+16%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Trailing PE: 12.47 | Current EPS (TTM): $2.79
Bull Case
$66.98
(+90%)
Analyst growth 75.0%, PE expands to 13.7
Base Case
$60.89
(+72%)
Market implied 75.0%, PE stable at 12.5
Bear Case
$23.66
(-33%)
Severe decline -20.0%, PE contracts to 10.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.2 to 9.6
Stabilization Target:
$46.88
(+32.7%)
PE Expansion Potential:
+32.7%
Share & Embed Analysis
Last updated: October 23, 2026 3:46 AM ET
Data refreshes hourly during market hours. Next update: 4:46 AM
Data refreshes hourly during market hours. Next update: 4:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INDV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 60 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 49 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 43 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 59 HOLD |
Advanced INDV Option Strategies
Professional options setups generated by AI based on today's INDV price and gamma walls.
